This GLP-1 Biotech Stock Could Give Novo Nordisk a Run for Its Money
Even if you might not fully understand what it means in a technical sense, you've probably heard of Novo Nordisk's (NYSE: NVO) medicines like Ozempic and Wegovy. These drugs have been tremendously helpful for people struggling with obesity and type 2 diabetes, respectively.
The underlying compound, called semaglutide, work by targeting the GLP-1 receptor in the human body. And while GLP-1-targeted therapies are relatively new, their success has been tremendous, which is why these drugs help generate billions of dollars for Novo Nordisk and peers like Eli Lilly every quarter.
That's why a handful of biotech companies are hard at work developing new GLP-1 drugs to get a slice of the action. If any of their candidates prove to be safer, more tolerable, or more effective than the existing options, they might just steal market share from the big dogs, supercharging their share price along the way.
Source Fool.com
